{
    "nct_id": "NCT06312176",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2024-03-15",
    "study_start_date": "2024-04-14",
    "study_completion_date": "",
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Biological: Pembrolizumab"
            },
            {
                "drug_name": "Drug: Nab-paclitaxel"
            },
            {
                "drug_name": "Drug: Liposomal doxorubicin"
            },
            {
                "drug_name": "Drug: Paclitaxel"
            },
            {
                "drug_name": "Drug: Sacituzumab tirumotecan"
            },
            {
                "drug_name": "Drug: Capecitabine"
            }
        ]
    },
    "long_title": "An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer",
    "last_updated": "2025-08-15",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE3",
    "principal_investigator": "NA, Winnie Yeo",
    "principal_investigator_institution": "Merck Sharp & Dohme LLC, CUHK",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [
        "BRE046"
    ],
    "protocol_no": "",
    "protocol_target_accrual": 1200,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Inclusion Criteria:",
        "* Has unresectable locally advanced or metastatic centrally-confirmed hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer",
        "* Has radiographic disease progression on one or more lines of endocrine therapy for unresectable locally advanced/metastatic HR+/HER2- breast cancer, with one in combination with a CDK4/6 inhibitor",
        "* Is a chemotherapy candidate",
        "* Has an eastern cooperative oncology group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization",
        "* Has adequate organ function",
        "* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy",
        "* Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load",
        "* Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable",
        "Exclude - Exclusion Criteria:",
        "Exclude - * Has breast cancer amenable to treatment with curative intent",
        "Exclude - * Has experienced an early recurrence (\\<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment",
        "Exclude - * Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications",
        "Exclude - * Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer",
        "Exclude - * Active autoimmune disease that has required systemic treatment in the past 2 years",
        "Exclude - * History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease",
        "Exclude - * Has an active infection requiring systemic therapy"
    ],
    "short_title": "A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "Merck Sharp & Dohme LLC",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer.\n\nThe primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants.",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "Arm A: Sacituzumab tirumotecan",
                        "arm_internal_id": 0,
                        "arm_description": "Participants receive 4 mg/kg of sacituzumab tirumotecan once every 2 weeks (Q2W) via intravenous (IV) infusion until progressive disease or discontinuation.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Sacituzumab tirumotecan",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Arm B:Pembrolizumab + Sacituzumab tirumotecan",
                        "arm_internal_id": 1,
                        "arm_description": "Participants receive 4 mg/kg of sacituzumab tirumotecan Q2W via IV infusion until progressive disease or discontinuation PLUS 400 mg of pembrolizumab once every 6 weeks (Q6W) via IV infusion for up to 18 administrations (up to \\~2 years).",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Sacituzumab tirumotecan",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Biological: Pembrolizumab",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Arm C: Treatment of Physician's Choice (TPC)",
                        "arm_internal_id": 2,
                        "arm_description": "At the physician's discretion, participants receive chemotherapy of 80 mg/m\\^2 of paclitaxel once every week (Q1W) via IV infusion OR 90 mg/m\\^2 of paclitaxel once every 4 weeks (Q4W) via IV infusion OR 100 mg/m\\^2 of nab-paclitaxel Q4W via IV infusion OR 1000 mg/m\\^2 of capecitabine every 3 weeks (Q3W) orally OR 50 mg/m\\^2 of liposomal doxorubicin once every 4 weeks (Q4W) via IV infusion, until progressive disease or discontinuation.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Paclitaxel",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Nab-paclitaxel",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "2",
                                "level_description": "Drug: Capecitabine",
                                "level_internal_id": 2,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "3",
                                "level_description": "Drug: Liposomal doxorubicin",
                                "level_internal_id": 3,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "and": [
                            {
                                "or": [
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Breast Neoplasm, NOS"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Breast Lobular Carcinoma In Situ"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Breast Ductal Carcinoma In Situ"
                                        }
                                    }
                                ]
                            },
                            {
                                "clinical": {
                                    "age_numerical": ">=18",
                                    "her2_status": "Negative",
                                    "er_status": "Positive",
                                    "pr_status": "Positive",
                                    "disease_status": [
                                        "Unresectable",
                                        "Locally Advanced",
                                        "Metastatic"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        ]
    }
}